EUDA Health Invests in Stem Cell Therapy Platform Expansion in China

summarizeSummary

EUDA Health's subsidiary entered a convertible loan agreement to invest up to RMB 6 million in Shenzhen Inno Immune, expanding its stem cell therapy platform and China strategy.

check_boxKey Events

• Strategic Convertible Loan Agreement

  EUDA Health's wholly-owned subsidiary entered a convertible loan agreement with Shenzhen Inno Immune Co., Ltd.

• Significant Investment for Expansion

  EUDA expects to invest up to RMB 6 million (approximately $0.84 million USD) in Shenzhen Inno Immune.

• Expansion of Stem Cell Therapy Platform

  The capital will be used to upgrade Shenzhen Inno's cGMP facility, establishing a core technology and operating hub for EUDA's regenerative medicine capabilities and China strategy.

• Future Equity Optionality

  The investment is structured as a convertible loan note, providing EUDA with the option to convert into an equity interest in Shenzhen Inno.

auto_awesomeAnalysis

This strategic investment positions EUDA Health to significantly enhance its regenerative medicine capabilities and establish a core technology hub in China. The convertible loan structure provides flexibility for future equity conversion, aligning with the company's disciplined approach to building long-term platforms in the fast-growing longevity sector. This move supports EUDA's mission to transform healthcare from reactive treatment to proactive, longevity-focused care in Asia.